#407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.
Key claim: Davidson argues that applying known LDL-lowering strategies earlier in life can prevent cardiovascular disease and help reduce Alzheimer’s risk, with particular attention to APOE4 carriers and emerging therapies.
Abstract
“I mean we have the knowledge to prevent heart disease now. It’s applying it earlier in life that really makes the difference. That’s my pitch to the 30-year-old, and there’s a lot of pushback.”‒ Michael Davidson The post #407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D. appeared first on Peter Attia MD.
Why this matters
This finding treats LDL/ApoB and APOE4 as a shared upstream biomarker layer for two nominally distinct diseases, arguing the measurement window for prevention opens decades earlier than typical clinical thresholds allow. It is a consolidation claim from a lipidologist rather than new trial data, but it reframes what the ‘boring blood panel’ is measuring — cumulative lifetime vascular and neurodegenerative risk rather than a snapshot cardiac number.